[Initial trial of tumor imaging using 123I-BMIPP: evaluation in soft tissue tumors]

To evaluate the usefulness of 123I-15-(p-iodophenyl)-3 (R, S)-methyl-pentadecanoic acid (123I-BMIPP) as a radiopharmaceutical for tumor imaging, six patients with liposarcomas and one patient with malignant fibrous histiocytoma were studied with 123I-BMIPP. 123I-BMIPP accumulated in the myxoid components of liposarcoma, while the well-differentiated components showed no increased uptake of 123I-BMIPP. 123I-BMIPP accumulated in viable parts of the tumor, while there was no uptake in the necrotic parts in one patient with malignant fibrous histiocytoma. This study indicated that 123I-BMIPP may be a special radiopharmaceutical for tumor imaging.